

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

INFORMATION DISCLOSURE STATEMENT		Docket Number: 2885/56	Confirmation Number: 8424
Application Number 10/009,649	Filing Date May 29, 2002	Examiner Thuy C. Dao	Art Unit 2192
Invention Title METHOD FOR INTERLEAVING A PROGRAM OVER A PLURALITY OF CELLS		Inventors Martin VORBACH et al.	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office via the Office electronic filing system on
Date: March 11, 2010
Signature: Eunice K. Chang/
Eunice K. Chang

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to Kenyon & Kenyon LLP, deposit account 11-0600.

This Information Disclosure Statement brings to the attention of the U.S. Patent and Trademark Office information that arose in the following patent litigation: *PACT XPP Technologies, AG v. XILINX, Inc., et al.*, (E.D. Texas Dec. 28, 2007) (No. 2:07cv563).

1. This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.

2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.

a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry,

was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

c. The required fee of \$180.00 under 37 CFR §1.17(p) is being paid by **credit card** to ensure consideration of the disclosed information. Any additional fees may be charged to Deposit Account No. 11-0600 of Kenyon & Kenyon LLP

3. English-language Abstracts of any non-English language references are attached hereto.

Respectfully submitted,

Date: March 11, 2010

/Aaron Grunberger/
Aaron Grunberger
Reg. No. 59,210

KENYON & KENYON LLP
One Broadway
New York, NY 20004
(212) 425-7200 telephone
(212) 425-5288 facsimile
CUSTOMER NUMBER 26646